Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average of $0.39

Daré Bioscience, Inc. (NASDAQ:DARE) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.39 and traded as low as $0.28. Daré Bioscience shares last traded at $0.29, with a volume of 415,941 shares.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DARE. Dawson James downgraded Daré Bioscience from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 30th. Brookline Capital Management downgraded Daré Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th. Finally, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Daré Bioscience in a research report on Monday, April 1st.

Daré Bioscience Trading Down 3.8 %

The business’s fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.39. The firm has a market cap of $28.77 million, a P/E ratio of -0.84 and a beta of 1.16.

Daré Bioscience (NASDAQ:DARE) last posted its earnings results on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $2.17 million. Analysts anticipate that Daré Bioscience, Inc. will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC acquired a new stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned approximately 7.37% of Daré Bioscience as of its most recent filing with the SEC. 6.70% of the stock is owned by institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.